| Style | Citing Format |
|---|---|
| MLA | Khurgami MR, et al.. "Caspofungin Therapy in Prosthetic Valve Endocarditis and Candidemia Due to Itraconazole-Resistant Candida Glabrata (Nakaseomyces Glabratus): A Case Report." Current Medical Mycology, vol. 11, no. , 2025, pp. -. |
| APA | Khurgami MR, Fattahi M, Beigi EH, Tamimi P, Ghaderi A, Hajiesmail G (2025). Caspofungin Therapy in Prosthetic Valve Endocarditis and Candidemia Due to Itraconazole-Resistant Candida Glabrata (Nakaseomyces Glabratus): A Case Report. Current Medical Mycology, 11(), -. |
| Chicago | Khurgami MR, Fattahi M, Beigi EH, Tamimi P, Ghaderi A, Hajiesmail G. "Caspofungin Therapy in Prosthetic Valve Endocarditis and Candidemia Due to Itraconazole-Resistant Candida Glabrata (Nakaseomyces Glabratus): A Case Report." Current Medical Mycology 11, no. (2025): -. |
| Harvard | Khurgami MR et al. (2025) 'Caspofungin Therapy in Prosthetic Valve Endocarditis and Candidemia Due to Itraconazole-Resistant Candida Glabrata (Nakaseomyces Glabratus): A Case Report', Current Medical Mycology, 11(), pp. -. |
| Vancouver | Khurgami MR, Fattahi M, Beigi EH, Tamimi P, Ghaderi A, Hajiesmail G. Caspofungin Therapy in Prosthetic Valve Endocarditis and Candidemia Due to Itraconazole-Resistant Candida Glabrata (Nakaseomyces Glabratus): A Case Report. Current Medical Mycology. 2025;11():-. |
| BibTex | @article{ author = {Khurgami MR and Fattahi M and Beigi EH and Tamimi P and Ghaderi A and Hajiesmail G}, title = {Caspofungin Therapy in Prosthetic Valve Endocarditis and Candidemia Due to Itraconazole-Resistant Candida Glabrata (Nakaseomyces Glabratus): A Case Report}, journal = {Current Medical Mycology}, volume = {11}, number = {}, pages = {-}, year = {2025} } |
| RIS | TY - JOUR AU - Khurgami MR AU - Fattahi M AU - Beigi EH AU - Tamimi P AU - Ghaderi A AU - Hajiesmail G TI - Caspofungin Therapy in Prosthetic Valve Endocarditis and Candidemia Due to Itraconazole-Resistant Candida Glabrata (Nakaseomyces Glabratus): A Case Report JO - Current Medical Mycology VL - 11 IS - SP - EP - PY - 2025 ER - |